Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

321.14
-9.4150-2.85%
Volume:29.25K
Turnover:9.49M
Market Cap:8.94B
PE:-24.97
High:333.06
Open:330.42
Low:318.25
Close:330.55
52wk High:392.70
52wk Low:40.12
Shares:27.85M
Float Shares:24.08M
Volume Ratio:0.80
T/O Rate:0.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.8634
EPS(LYR):-13.4758
ROE:-38.86%
ROA:-25.65%
PB:6.67
PE(LYR):-23.83

Loading ...

Praxis says elsunersen cuts seizures 77% in SCN2A DEE EMBRAVE Part A trial

Reuters
·
Apr 06

Praxis Precision Medicines Inc - Elsunersen Well-Tolerated With No Drug-Related Serious Adverse Events up to 8 Mg

THOMSON REUTERS
·
Apr 06

Praxis Precision Medicines Announces Positive Results From the Embrave Part a Trial of Elsunersen in Patients With Scn2a Early-Onset Developmental and Epileptic Encephalopathy

THOMSON REUTERS
·
Apr 06

How Investors May Respond To Praxis (PRAX) FDA Priority Review For Rare Pediatric Epilepsy Drug

Simply Wall St.
·
Apr 04

Praxis grants inducement RSUs covering 3,558 shares to 18 new employees

Reuters
·
Apr 03

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 03

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), PepGen Inc. (PEPG) and Omeros (OMER)

TIPRANKS
·
Apr 01

Jefferies Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

TIPRANKS
·
Mar 31

Analysts Offer Insights on Healthcare Companies: MannKind (MNKD) and Praxis Precision Medicines (PRAX)

TIPRANKS
·
Mar 31

Praxis Precision Medicines Secures US FDA Priority Review for Epilepsy Drug Application

MT Newswires Live
·
Mar 31

Praxis Precision announces FDA acceptance for priority review of relutrigine NDA

TIPRANKS
·
Mar 31

Praxis NDA for relutrigine wins FDA priority review, PDUFA date set for Sept. 27, 2026

Reuters
·
Mar 31

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients With Scn2a and Scn8a Dees

THOMSON REUTERS
·
Mar 31

Praxis Precision Medicines Inc - Relutrigine Emerald Trial for Broad Dees Expected to Complete by End of 2026

THOMSON REUTERS
·
Mar 31

Praxis Precision Medicines Inc - FDA Assigns Pdufa Target Action Date of Sept 27, 2026 for Relutrigine

THOMSON REUTERS
·
Mar 31

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Biohaven Ltd. (BHVN) and Siemens Healthineers AG (OtherSEMHF)

TIPRANKS
·
Mar 11